mexiletine has been researched along with Disease Models, Animal in 39 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 7.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 7.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "Potential utility of mexiletine for the treatment of sparfloxacin-induced long QT syndrome was assessed using the in vivo halothane-anesthetized canine model." | 7.72 | Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Takahara, A, 2003) |
| "The influence of mexiletine hydrochloride on herpes-related pain responses was examined using mice infected with herpes virus." | 7.72 | Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus. ( Asano, K; Hisamitsu, T; Sameshima, T; Shirasawa, H, 2003) |
| "The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias." | 7.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "Mexiletine treatment prevented the increase in lipid peroxidation and cerebral vasospasm." | 5.33 | The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage. ( Altinors, N; Atalay, B; Aydin, MV; Bavbek, M; Caner, H; Ozen, O; Sen, O, 2006) |
| "Mexiletine has beneficial effects on myotonia." | 5.30 | Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia. ( Camerino, DC; De Luca, A; Desaphy, JF; Tortorella, V, 1999) |
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 3.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| "The effect of the cyclooxygenase-2 (COX-2) inhibitor etodolac on the mechanical allodynia induced by paclitaxel was investigated in mice and compared with the effects of the nonselective COX inhibitors indomethacin and diclofenac, the selective COX-2 inhibitor celecoxib, the calcium channel α(2)δ subunit inhibitor pregabalin, the sodium channel blocker mexiletine, and the serotonin-norepinephrine reuptake inhibitor duloxetine." | 3.78 | Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. ( Banno, K; Inoue, N; Ito, S; Kotera, T; Kyoi, T; Nakamura, A; Nogawa, M; Sasagawa, T; Tajima, K; Takahashi, Y; Ueda, M; Yamashita, Y, 2012) |
| "It has been suggested that both pacing and treatment with mexiletine may reduce torsade de pointes (TdP) arrhythmias in patients with long QT syndrome 3 (LQT3), but it is not fully understood how these interventions could prevent TdP." | 3.72 | Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. ( Breithardt, G; Carmeliet, E; Carmeliet, P; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Nuyens, D; Ottenhof, A; Rossenbacker, T, 2003) |
| "Potential utility of mexiletine for the treatment of sparfloxacin-induced long QT syndrome was assessed using the in vivo halothane-anesthetized canine model." | 3.72 | Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Takahara, A, 2003) |
| "The influence of mexiletine hydrochloride on herpes-related pain responses was examined using mice infected with herpes virus." | 3.72 | Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus. ( Asano, K; Hisamitsu, T; Sameshima, T; Shirasawa, H, 2003) |
| "The arrhythmogenic and electrophysiologic properties of sotalol, a class III antiarrhythmic drug, administered alone and in combination with mexiletine, a class I antiarrhythmic drug, were compared in conscious dogs predisposed to torsade de pointes arrhythmias." | 3.69 | Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. ( Chézalviel-Guilbert, F; Davy, JM; Poirier, JM; Weissenburger, J, 1995) |
| "Left middle cerebral artery occlusion following microcraniectomy and simultaneous bilateral carotid artery occlusion were performed." | 1.35 | The preventive effect of mexiletine on cerebral ischemic injury following experimental middle cerebral artery occlusion. ( Akar, A; Altinors, N; Caner, H; Cansever, T; Gulsen, S; Kabatas, S; Ozger, O; Yilmaz, C, 2009) |
| " Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain." | 1.34 | Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. ( Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Gonzalez, E; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Macintyre, DE; Martin, WJ; McGowan, E; Ok, H; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2007) |
| "Mexiletine treatment prevented the increase in lipid peroxidation and cerebral vasospasm." | 1.33 | The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage. ( Altinors, N; Atalay, B; Aydin, MV; Bavbek, M; Caner, H; Ozen, O; Sen, O, 2006) |
| "Rats treated with mexiletine, EGb 761, and mexiletine plus EGb 761 had significantly lower MDA levels than the control group (P<0." | 1.32 | Effects of mexiletine, ginkgo biloba extract (EGb 761), and their combination on experimental head injury. ( Akdemir, H; Koç, RK; Menkü, A; Narin, F; Saraymen, R; Tayfur, V, 2003) |
| "), a selective protein kinase C inhibitor, significantly inhibited intrathecal fenvalerate-induced nociceptive behavior with a rightward shift of the dose-response curve for fenvalerate-induced nociceptive behavior to the level those observed in non-diabetic mice." | 1.31 | Modification of the fenvalerate-induced nociceptive response in mice by diabetes. ( Iguchi, E; Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2002) |
| "Mexiletine has beneficial effects on myotonia." | 1.30 | Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia. ( Camerino, DC; De Luca, A; Desaphy, JF; Tortorella, V, 1999) |
| "Protection from arrhythmias seems to be related to the combined presence of a noncompetitive adrenergic blockade associated with salutary effects on coronary circulation." | 1.27 | The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. ( Schwartz, PJ; Vanoli, E; Zaza, A; Zuanetti, G, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (7.69) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 22 (56.41) | 29.6817 |
| 2010's | 7 (17.95) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Hoyt, SB | 2 |
| London, C | 2 |
| Ok, H | 1 |
| Gonzalez, E | 1 |
| Duffy, JL | 2 |
| Abbadie, C | 4 |
| Dean, B | 1 |
| Felix, JP | 2 |
| Garcia, ML | 2 |
| Jochnowitz, N | 2 |
| Karanam, BV | 2 |
| Li, X | 2 |
| Lyons, KA | 2 |
| McGowan, E | 2 |
| Macintyre, DE | 1 |
| Martin, WJ | 3 |
| Priest, BT | 2 |
| Smith, MM | 2 |
| Tschirret-Guth, R | 1 |
| Warren, VA | 2 |
| Williams, BS | 1 |
| Kaczorowski, GJ | 2 |
| Parsons, WH | 1 |
| Thomas-Fowlkes, BS | 1 |
| Wu, YJ | 1 |
| Guernon, J | 1 |
| McClure, A | 1 |
| Luo, G | 1 |
| Rajamani, R | 1 |
| Ng, A | 1 |
| Easton, A | 1 |
| Newton, A | 1 |
| Bourin, C | 1 |
| Parker, D | 1 |
| Mosure, K | 1 |
| Barnaby, O | 1 |
| Soars, MG | 1 |
| Knox, RJ | 1 |
| Matchett, M | 1 |
| Pieschl, R | 1 |
| Herrington, J | 1 |
| Chen, P | 1 |
| Sivarao, DV | 1 |
| Bristow, LJ | 1 |
| Meanwell, NA | 1 |
| Bronson, J | 1 |
| Olson, R | 1 |
| Thompson, LA | 1 |
| Dzierba, C | 1 |
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Frommeyer, G | 1 |
| Garthmann, J | 1 |
| Ellermann, C | 1 |
| Dechering, DG | 1 |
| Kochhäuser, S | 1 |
| Reinke, F | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Eckardt, L | 1 |
| Desaphy, JF | 3 |
| Carbonara, R | 1 |
| Costanza, T | 1 |
| Conte Camerino, D | 1 |
| Weston, RM | 1 |
| Subasinghe, KR | 1 |
| Staikopoulos, V | 1 |
| Jarrott, B | 1 |
| Yilmaz, C | 1 |
| Ozger, O | 1 |
| Kabatas, S | 1 |
| Cansever, T | 1 |
| Akar, A | 1 |
| Gulsen, S | 1 |
| Altinors, N | 2 |
| Caner, H | 3 |
| Batcioglu, K | 1 |
| Uyumlu, AB | 1 |
| Satilmis, B | 1 |
| Yildirim, B | 1 |
| Yucel, N | 1 |
| Demirtas, H | 1 |
| Onkal, R | 1 |
| Guzel, RM | 1 |
| Djamgoz, MB | 1 |
| Ito, S | 1 |
| Tajima, K | 1 |
| Nogawa, M | 1 |
| Inoue, N | 1 |
| Kyoi, T | 1 |
| Takahashi, Y | 1 |
| Sasagawa, T | 1 |
| Nakamura, A | 1 |
| Kotera, T | 1 |
| Ueda, M | 1 |
| Yamashita, Y | 1 |
| Banno, K | 1 |
| Yoshida, H | 1 |
| Sugiyama, A | 2 |
| Satoh, Y | 2 |
| Ishida, Y | 1 |
| Kugiyama, K | 1 |
| Hashimoto, K | 2 |
| Kamei, J | 1 |
| Iguchi, E | 1 |
| Sasaki, M | 1 |
| Zushida, K | 1 |
| Morita, K | 1 |
| Tanaka, S | 1 |
| Erichsen, HK | 1 |
| Hao, JX | 1 |
| Xu, XJ | 2 |
| Blackburn-Munro, G | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 1 |
| Nuyens, D | 1 |
| Rossenbacker, T | 1 |
| Ottenhof, A | 1 |
| Haverkamp, W | 1 |
| Breithardt, G | 1 |
| Carmeliet, E | 1 |
| Carmeliet, P | 1 |
| Menkü, A | 1 |
| Koç, RK | 1 |
| Tayfur, V | 1 |
| Saraymen, R | 1 |
| Narin, F | 1 |
| Akdemir, H | 1 |
| Takahara, A | 1 |
| Asano, K | 1 |
| Sameshima, T | 1 |
| Shirasawa, H | 1 |
| Hisamitsu, T | 1 |
| De Luca, A | 2 |
| Pierno, S | 1 |
| Liantonio, A | 1 |
| Natuzzi, F | 1 |
| Didonna, MP | 1 |
| Ferrannini, E | 1 |
| Jockusch, H | 1 |
| Franchini, C | 1 |
| Lentini, G | 1 |
| Corbo, F | 1 |
| Tortorella, V | 2 |
| Camerino, DC | 2 |
| Niwano, S | 2 |
| Inuo, K | 2 |
| Morohoshi, Y | 2 |
| Nakayama, S | 2 |
| Yuge, M | 1 |
| Imaki, R | 1 |
| Izumi, T | 2 |
| Lindia, JA | 1 |
| Köhler, MG | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Kinchington, PR | 1 |
| Krah, DL | 1 |
| Fleetwood-Walker, SM | 1 |
| Head, CE | 1 |
| Balasubramaniam, R | 1 |
| Thomas, G | 1 |
| Goddard, CA | 1 |
| Lei, M | 1 |
| Colledge, WH | 1 |
| Grace, AA | 1 |
| Huang, CL | 1 |
| Sen, O | 1 |
| Aydin, MV | 1 |
| Ozen, O | 1 |
| Atalay, B | 2 |
| Bavbek, M | 1 |
| Ates, O | 1 |
| Cayli, SR | 1 |
| Gurses, I | 1 |
| Turkoz, Y | 1 |
| Tarim, O | 1 |
| Cakir, CO | 1 |
| Kocak, A | 1 |
| Can, A | 1 |
| Cekinmez, M | 1 |
| Tanimoto-Mori, S | 1 |
| Nakazato-Imasato, E | 1 |
| Toide, K | 1 |
| Kita, Y | 1 |
| Chézalviel-Guilbert, F | 1 |
| Davy, JM | 1 |
| Poirier, JM | 1 |
| Weissenburger, J | 1 |
| Komori, S | 1 |
| Sawanobori, T | 1 |
| Tamura, K | 1 |
| Kane, KA | 1 |
| Parratt, JR | 1 |
| Priori, SG | 1 |
| Napolitano, C | 1 |
| Paganini, V | 1 |
| Cantù, F | 1 |
| Schwartz, PJ | 2 |
| Shimizu, W | 1 |
| Antzelevitch, C | 1 |
| Horiuchi, J | 1 |
| Sato, Y | 1 |
| Wu, WP | 1 |
| Nordmark, J | 1 |
| Wiesenfeld-Hallin, Z | 1 |
| Ikeda, K | 1 |
| Kojima, J | 1 |
| Saito, J | 1 |
| Masuda, T | 1 |
| Henning, B | 1 |
| Merx, W | 1 |
| de Bakker, JM | 1 |
| Effert, S | 1 |
| Hashimoto, H | 1 |
| Satoh, N | 1 |
| Nakashima, M | 1 |
| Uprichard, AC | 1 |
| Harron, DW | 1 |
| Vanoli, E | 1 |
| Zaza, A | 1 |
| Zuanetti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mexiletine and Disease Models, Animal
| Article | Year |
|---|---|
Molecular biology of the long QT syndrome: impact on management.
Topics: Action Potentials; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artifici | 1997 |
38 other studies available for mexiletine and Disease Models, Animal
| Article | Year |
|---|---|
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Topics: Animals; Benzodiazepinones; Biological Availability; Disease Models, Animal; Dogs; Drug Evaluation, | 2007 |
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
Topics: Animals; Benzazepines; Disease Models, Animal; Neuralgia; Rats; Sodium Channel Blockers | 2013 |
Discovery of non-zwitterionic aryl sulfonamides as Na
Topics: Administration, Oral; Animals; Chronic Pain; Disease Models, Animal; Dose-Response Relationship, Dru | 2017 |
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disea | 2018 |
Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs.
Topics: Animals; Carbamazepine; Disease Models, Animal; Flecainide; HEK293 Cells; Humans; Mexiletine; Muscle | 2014 |
Design and assessment of a potent sodium channel blocking derivative of mexiletine for minimizing experimental neuropathic pain in several rat models.
Topics: Analgesics; Animals; Disease Models, Animal; Drug Discovery; Drug Evaluation, Preclinical; Male; Mex | 2009 |
The preventive effect of mexiletine on cerebral ischemic injury following experimental middle cerebral artery occlusion.
Topics: Animals; Anti-Arrhythmia Agents; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; I | 2009 |
Oxidative stress in the in vivo DMBA rat model of breast cancer: suppression by a voltage-gated sodium channel inhibitor (RS100642).
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Disease Models, Animal; Female; Glutathione Peroxidase; M | 2012 |
Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia.
Topics: Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Disease Models, Animal; Drug Int | 2012 |
Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac | 2002 |
Modification of the fenvalerate-induced nociceptive response in mice by diabetes.
Topics: Animals; Behavior, Animal; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Re | 2002 |
A comparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain.
Topics: Analgesics; Analysis of Variance; Anesthetics, Local; Animals; Disease Models, Animal; Dose-Response | 2003 |
Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Anim | 2003 |
Effects of mexiletine, ginkgo biloba extract (EGb 761), and their combination on experimental head injury.
Topics: Animals; Brain Edema; Disease Models, Animal; Drug Therapy, Combination; Ginkgo biloba; Head Injurie | 2003 |
Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Blood Pressure; Bundle of | 2003 |
Attenuating effect of mexiletine hydrochloride on herpetic pain in mice infected with herpes simplex virus.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; H | 2003 |
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.
Topics: Action Potentials; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Do | 2004 |
Mexiletine protects myocardium during acute ischemia by opening sarcolemmal K-ATP channel: studies in closed-chest acute ischemia model in rabbits.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; ATP-Binding Cassette Transporters; Disease Models, A | 2004 |
Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats.
Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Gan | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Art | 2005 |
The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage.
Topics: Analysis of Variance; Animals; Anti-Arrhythmia Agents; Apoptosis; Arteries; Disease Models, Animal; | 2006 |
Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Lipid Peroxidation; Locomotion; Male; Mexiletine; | 2007 |
Attenuation of microtubule associated protein-2 degradation after mild head injury by mexiletine and calpain-2 inhibitor.
Topics: Animals; Brain; Calpain; Cytoskeleton; Disease Models, Animal; Head Injuries, Closed; Immunologic Te | 2007 |
Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Calcium Channel Blockers; Chronic Disease; Cold Tempe | 2008 |
Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
Topics: Analysis of Variance; Animals; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Drug Inte | 1995 |
Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Topics: Amino Alcohols; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Dise | 1994 |
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dogs; Dose-R | 1998 |
Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia.
Topics: Animals; Anti-Arrhythmia Agents; Cnidarian Venoms; Disease Models, Animal; In Vitro Techniques; Memb | 1999 |
[Effect of mexiletine on spontaneous sensory afferent activity in spontaneous diabetic rats (WBN/Kob rats)].
Topics: Action Potentials; Anesthetics, Local; Animals; Anti-Arrhythmia Agents; Depression, Chemical; Diabet | 2000 |
Lack of stereoselectivity for the antiallodynic effect of mexiletine in spinally injured rats.
Topics: Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Drug Evaluation, Preclinical; Female; | 2000 |
Cardioprotective effect of mexiletine in acute myocardial ischemia tudies in the rabbit closed chest ischemia mode.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Coronary Angiography; Coronary V | 2002 |
[The antifibrillatory effect of mexiletine (Kö 1173) in experimentally induced myocardial infarct].
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Mexiletine; Myocardial Infarction; Propy | 1976 |
Coupling interval-related effects of class I antiarrhythmic drugs, mexiletine, cibenzoline and disopyramide, on ventricular activation in canine myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Disopyramide; Dogs; Electric Stimulation; E | 1991 |
Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Coronary Circulation; Disease Models, Ani | 1989 |
The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Disease M | 1985 |